2026-525566-21-00招募中2 期
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
Theriva Biologics S.L.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2026年6月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- • Safety and tolerability of the administration regimen of VCN-01 administered every 56 days, with three planned doses, combined with SoC GnP cycles.
研究概览
简要总结
• To evaluate the safety and tolerability of VCN-01 administered every 56 days, with three planned doses, combined with GnP treatment in the participant Population. • To evaluate the pharmacodynamic of VCN-01 through the analysis of its viral genome levels in blood.
研究设计
- 分配方式
- Na
- 主要目的
- End of Trial
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained prior to initiating any study-specific procedures or assessments.
- •Male or female patients aged 18 years or over.
- •Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) de novo and who have not received any previous treatment for their pancreatic cancer for which the established therapy is gemcitabine/nab-paclitaxel (clinical SoC).
- •Patients must have at least one measurable tumor lesion that can be imaged for assessments according to RECIST 1.
- •ECOG performance status of 0 or 1 at enrollment.
- •Must be willing to comply with the study treatment regimen, including prophylactic medications, and study procedures.
- •Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment: Hematology: • Leukocytes ≥3.0x103 mcL • Absolute neutrophil count ≥1.5x10⁹/L • Hemoglobin ≥9 g/dL • Platelets ≥100x10⁹/L Coagulation: • Prothrombin time or international normalized ratio ≤1x upper limit of normal (ULN) • Activated partial thromboplastin time ≤1.2xULN Hepatic: • Total bilirubin ≤1.5xULN • ALT and AST ≤2.5xULN (<5xULN is acceptable if liver metastases are present) Renal: • Serum creatinine ≤1.5xULN; or, • If serum creatinine >1.5xULN, an estimated creatinine clearance >50 mL/min using the Cockcroft and Gault formula Nutritional: • Serum Albumin ≥30 g/L
- •Adequate left ventricular ejection fraction (LVEF) ≥ 50% measured by ECHO or MUGA and QT interval corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women.
排除标准
- •Unwillingness to complete the study procedures for geographic, psychiatric, or social reasons.
- •Patients with pre-existing sensory neuropathy >G1
- •Clinical evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic event during the Screening Period. Patients with superficial vein thrombosis are eligible to participate.
- •Patients with uncontrolled coagulopathy.
- •Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical study due to concerns over safety or potential non-compliance with clinical study procedures.
- •A female patient, who is pregnant or lactating. - Female patients of reproductive potential must agree to use a highly effective method of birth control. Male patients must agree to use condoms.
- •Treatment with live attenuated vaccines in the last 3 weeks before the administration of IMP.
- •Treatment with an adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of IMP.
- •Treatment with another investigational agent within five of that investigational agent’s half-lives prior to the randomization.
- •Chronic immunosuppressive therapy; except that: Inhaled corticosteroids are permitted; Oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day are permitted; Dexamethasone up to a maximum dose of 1 mg/day is permitted.
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: Palliative radiotherapy for pain is permitted; Placement of a biliary stent/tube is permitted.
- •Subjects, for whom first line treatment options other than the combination gemcitabine/nab-paclitaxel are recommended by the investigator.
- •Patients who, in the opinion of the investigator, have symptoms or signs suggesting clinically unacceptable deterioration during the Screening Period.
- •Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes: Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice. Patients with past or resolved TB are eligible to participate. Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result). HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate; Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate; Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment. Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]). Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate; Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA). Human immunodeficiency virus (positive HIV 1/2 antibodies) Patients with HIV with undetectable viral load are eligible to participate.
- •Known chronic liver disease (e.g. liver cirrhosis, liver fibrosis, chronic hepatitis); except that: Patients with fatty liver disease are eligible to participate if their liver transaminases meet inclusion criterion
- •Concurrent malignant hematologic or solid disease; except that: Patients with a prior history of cancer are eligible to participate if they are in complete remission from their prior cancer for at least 3 years.
- •Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency.
- •Patients with untreated brain metastases and/or leptomeningeal carcinomatosis with progressive symptoms despite corticosteroid coverage; except that: Patients with brain metastases with stable symptoms are eligible to participate.
- •Patients with previous pneumonitis or interstitial lung disease.
研究组 & 干预措施
VCN-01
Test
干预措施: VCN-01 (Drug)
结局指标
主要结局
• Safety and tolerability of the administration regimen of VCN-01 administered every 56 days, with three planned doses, combined with SoC GnP cycles.
• Safety and tolerability of the administration regimen of VCN-01 administered every 56 days, with three planned doses, combined with SoC GnP cycles.
• Pharmacodynamics of VCN-01 following intravenous administration and characterization of the pharmacokinetic profile across the three planned doses.
• Pharmacodynamics of VCN-01 following intravenous administration and characterization of the pharmacokinetic profile across the three planned doses.
次要结局
- • Proportion of participants who have a partial or complete response confirmed by RECIST 1.1 to the combination therapy (Objective response rate (ORR)).
- • Progression Free Survival (PFS), defined as the time from the first VCN-01 dose until radiologically confirmed progressive disease (according to RECIST version 1.1) or death by any cause.
- • Duration of response (DoR) defined as the time from the first partial response or complete response until radiologically confirmed progressive disease (according to RECIST version 1.1) or death by any cause.
- • Landmark one-year and 18-months Overall survival (OS)
- • Disease control rate (DCR), defined as the proportion of participants whose best response is either stable disease or partial response or complete response (according to RECIST version 1.1).
- • Changes in serum levels of neutralizing anti-adenovirus antibodies (Anti-Ad-NAbs)
- • Changes in serum levels of tumor marker CA 19-9.
研究者
Manel
Scientific
Theriva Biologics S.L.
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED)Thyroid eye disease2023-507217-10-00Viridian Therapeutics Inc.170
尚未招募
2 期
A Comparative Non Randomized clinical trial on Akkini Chooranam and Narambu Pidikku Ottradam and Varmam Adangal alone in the management of Korai Vatham (Lumbar Spondylosis) for the patients reporting at Government Siddha Medical college and Hospital PalayamkottaiCTRI/2026/04/107449Government Siddha Medical College and Hospital Palayamkottai40
尚未招募
2 期
DNV001 Injection in Patients With HypercholesterolemiaNCT07391722Hangzhou Dinovate Biotech Co., Ltd120
招募中
1 期
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab ImmunotherapyRectal CancerNCT07561060Fudan University50
尚未招募
3 期
To study if iptacopan is safe, tolerable and effective in patients with aHUSCTRI/2024/07/070874Novartis Healthcare Pvt Ltd100